Active Ingredient History

NOW
  • Now
Fostamatinib is a pro-drug of a Syk inhibitor R406 initially developed by Rigel Pharmaceuticals, but then in-licensed by AstraZeneca. It reached phase III of clinical trials for such diseases as Rheumatoid Arthritis and Immune Thrombocytopenic Purpura, however, AstraZeneca decided not to proceed with regulatory filings and return the rights to the compound to Rigel Pharmaceuticals. In 2018 the drug was approved by the FDA for treatment of chronic immune thrombocytopenia. Fostamatinib is being developed for Autoimmune Hemolytic Anemia (phase II), graft versus host disease (phase I) and ovarian cancer (phase I).   NCATS

  • SMILES: O.O.O.O.O.O.[Na+].[Na+].COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(=O)([O-])[O-])c4n3)n2)cc(OC)c1OC
  • InChIKey: ZQGJCHHKJNSPMS-UHFFFAOYSA-L
  • Mol. Mass: 732.52
  • ALogP: 3.09
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$121.6607 - $159.9398
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

fostamatinib | fostamatinib disodium | r788 | r-788 | r 788 compound | r788 compound | r-788 free acid | r-788 sodium | r935788 | r-935788 | r-935788 free acid | r-935788 sodium

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue